Civic Intelligence

Aveni Foundation

990EZ • Fiscal year 2022 • EIN 83-0731767

Jan 01, 2022 to Dec 31, 2022 • Filed on Nov 01, 2023

Organization ProfileWWW.AVENIFOUNDATION.ORG
2700 Neilson Way 1227Santa Monica, CA 90405

(818) 726-3278

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on this filing.

Source year 2022

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on this filing.

Source year 2022

Net Margin

6th percentile

-116%

Higher net margin than 6% of similar nonprofits.

2022 filings • 501(c)3 • <$500k nonprofits • Source year 2022

Top Officer Pay

78th percentile

$0

Higher top officer pay than 78% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2022 filings • 501(c)3 • <$500k nonprofits • Source year 2022

Asset Growth

12th percentile

-42%

Faster asset growth than 12% of similar nonprofits.

2022 filings • 501(c)3 • <$500k nonprofits • Annualized from 2021 to 2022

Revenue Growth

6th percentile

-74%

Faster revenue growth than 6% of similar nonprofits.

2022 filings • 501(c)3 • <$500k nonprofits • Annualized from 2021 to 2022

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Down

$144,595

Down $105,098 (-42%) from 2021

Net Assets

Down

$144,595

Down $105,098 (-42%) from 2021

Liabilities

-

No earlier filing loaded for comparison.

Revenue And Expenses
Liabilities / RevenueScore unavailableNet Margin6th percentile

Revenue

Down

$90,641

Down $259,728 (-74%) from 2021

Expenses

Up

$195,739

Up $30,350 (+18%) from 2021

Net Income

Down

-$105,098

Down $290,078 (-157%) from 2021

Historical Trend

Balance Sheet Trend

Asset Growth12th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$1.0M$500K$0Assets 2018: $9,058Net Assets 2018: $9,0582018Assets 2019: $267,529Liabilities 2019: $2,535Net Assets 2019: $264,9942019Assets 2020: $64,741Liabilities 2020: $2,500Net Assets 2020: $62,2412020Assets 2021: $249,693Liabilities 2021: $0Net Assets 2021: $249,6932021Assets 2022: $144,595Net Assets 2022: $144,5952022Assets 2023: $381,884Liabilities 2023: $274Net Assets 2023: $381,6102023Assets 2024: $841,340Liabilities 2024: $7,450Net Assets 2024: $833,8902024

Highlighted filing

2022

Assets$144,595
Liabilities-
Net Assets$144,595
Open 2022 Filing

Operations Trend

Revenue Growth6th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$1.5M$1.0M$500K$0-$500KRevenue 2018: $12,825Expenses 2018: $3,767Net Income 2018: $9,0582018Revenue 2019: $1,176,314Expenses 2019: $920,378Net Income 2019: $255,9362019Revenue 2020: $149,238Expenses 2020: $351,991Net Income 2020: -$202,7532020Revenue 2021: $350,369Expenses 2021: $165,389Net Income 2021: $184,9802021Revenue 2022: $90,641Expenses 2022: $195,739Net Income 2022: -$105,0982022Revenue 2023: $708,687Expenses 2023: $471,672Net Income 2023: $237,0152023Revenue 2024: $1,148,817Expenses 2024: $696,537Net Income 2024: $452,2802024

Highlighted filing

2022

Revenue$90,641
Expenses$195,739
Net Income-$105,098
Open 2022 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2022 to Dec 31, 2022
Signed
Nov 1, 2023
Return Version
2022v5.0
Gross Receipts
$90,641
Mission and Program Overview

Mission

The Aveni Foundation is committed to expediting development of gene-targeted therapies for metastatic cancers and other unmet medical needs.

Program Services

DescriptionGrantsExpenses
THE AVENIFOUNDATION REPORTED THE PERFORMANCE OF TWO CLINICAL STUDIES:1. Compassionate Use of Intravenous DeltaRex-G Tumor-Targeted Retrovector Bearing a Cytocidal Dominant Negative Cyclin G1 Inhibitor for Advanced Sarcoma, Pancreatic Cancer, Non-small Cell Lung Cancer, Breast Cancer, Cholangiocarcinoma, Basal Cell Carcinoma (Single Use INDs)2. Blessed: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma for an Intermediate Size Population (NCT04091295)INTERIM RESULTS SHOWED THE FOLLOWING:Eighteen patients were enrolled, 10 sarcoma, 2 pancreatic adenocarcinoma, 1 non-small cell lung cancer, 2 breast carcinoma, 1 prostate cancer, 1 cholangiocarcinoma and 1 basal cell carcinoma. Fifteen patients were enrolled in Study 1 single patient use IND, 3 patients were enrolled in Study 2. Two patients were initially enrolled in Study 2, and later enrolled in Study 1. Twelve of 18 enrolled patients were treated with DeltaRex-G monotherapy or in combination with FDA approved cancer therapies. Six of 18 enrolled patients are alive, 2 with breast cancer are alive in complete remission, 2 with sarcoma are alive with stable disease, 1with basal cell carcinoma is alive with partial response and 1 with sarcoma is alive with progressive disease. Three patients died of progressive disease before receiving DeltaRex-G. Two patients withdrew without receiving DeltaRex-G.-$171,825
Compensation and Service Providers
Top Officer Pay78th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
ERLINDA GORDONDirectorFT$0--
RICHIE TUAZONTreasurer-$0--
MYRNA AQUITNIASecretary-$0--
Filing and Contact Details

Filer

Filer Name
Aveni Foundation
EIN
83-0731767
Phone
8187263278
Address
2700 NEILSON WAY 1227, SANTA MONICA, CA 90405

Signing Officer

Name
Erlinda M Gordon
Title
Director
Signed
2023-11-01
Discuss with paid preparer
Yes

Preparer

Firm
First Advisor Inc
Address
655 N CENTRAL AVE 17TH FLOOR, GLENDALE, CA 91203
Preparer
Lauren Lee
Phone
8183307722
Supplemental Narrative

Additional Explanations

Other Expenses.1001

“Advertising and Promotion $312”

Other Expenses.1002

“Office Expenses $598”

Other Expenses.1012

“Insurance $14759”

Other Expenses.1

“VECTOR PRODUCTION $72514”

Other Expenses.2

“QUALITY CONTROL $35000”

Other Expenses.3

“Chief science officer $20000”

Other Expenses.4

“Clinic research coordinator $13278”

Other Expenses.5

“director, business development $5000”

Other Expenses.6

“Procurement associate $5000”

Other Expenses.7

“RENT $4422”

Other Expenses.8

“LAB EQUIPMENT $3000”

Other Expenses.9

“VECTOR TITER ASSAY $2610”

Other Expenses.10

“Research lab supplies $2395”

Other Expenses.12

“Research equipment rent $1620”

Other Expenses.13

“LAB FEES $1325”

Other Expenses.14

“Reference materials $1029”

Other Expenses.15

“administrative assistant $775”

Raw XML Appendix175 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0ERLINDA M GORDON
IRS990EZ/BooksInCareOfDetail/PhoneNum08187263278
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt02700 NEILSON WAY 1227
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0SANTA MONICA
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd090405
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0249693
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0144595
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt090625
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-105098
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt09851
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0249693
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0144595
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt090641
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt016
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0249693
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0144595
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0249693
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0144595
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt040.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0ERLINDA GORDON
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1RICHIE TUAZON
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2MYRNA AQUITNIA
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Treasurer
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Secretary
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt0183637
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0THE AVENI FOUNDATION IS COMMITTED TO EXPEDITING DEVELOPMENT OF GENE-TARGETED THERAPIES FOR METASTATIC CANCERS AND OTHER UNMET MEDICAL NEEDS.
IRS990EZ/PrintingPublicationsPostageAmt02251
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0THE AVENIFOUNDATION REPORTED THE PERFORMANCE OF TWO CLINICAL STUDIES:1. Compassionate Use of Intravenous DeltaRex-G Tumor-Targeted Retrovector Bearing a Cytocidal Dominant Negative Cyclin G1 Inhibitor for Advanced Sarcoma, Pancreatic Cancer, Non-small Cell Lung Cancer, Breast Cancer, Cholangiocarcinoma, Basal Cell Carcinoma (Single Use INDs)2. Blessed: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma for an Intermediate Size Population (NCT04091295)INTERIM RESULTS SHOWED THE FOLLOWING:Eighteen patients were enrolled, 10 sarcoma, 2 pancreatic adenocarcinoma, 1 non-small cell lung cancer, 2 breast carcinoma, 1 prostate cancer, 1 cholangiocarcinoma and 1 basal cell carcinoma. Fifteen patients were enrolled in Study 1 single patient use IND, 3 patients were enrolled in Study 2. Two patients were initially enrolled in Study 2, and later enrolled in Study 1. Twelve of 18 enrolled patients were treated with DeltaRex-G monotherapy or in combination with FDA approved cancer therapies. Six of 18 enrolled patients are alive, 2 with breast cancer are alive in complete remission, 2 with sarcoma are alive with stable disease, 1with basal cell carcinoma is alive with partial response and 1 with sarcoma is alive with progressive disease. Three patients died of progressive disease before receiving DeltaRex-G. Two patients withdrew without receiving DeltaRex-G.
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt0171825
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0CA
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt0195739
IRS990EZ/TotalProgramServiceExpensesAmt0171825
IRS990EZ/TotalRevenueAmt090641
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.AVENIFOUNDATION.ORG
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt090625
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt0350364
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0149231
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt01176155
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt012825
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt01779200
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt00
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.00000
IRS990ScheduleA/PublicSupportTotal170Amt01779200
IRS990ScheduleA/SubstantialContributorsTotAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt090625
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt0350364
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0149231
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt01176155
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt012825
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt01779200
IRS990ScheduleA/TotalSupportAmt01779200
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Advertising and Promotion $312
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Office Expenses $598
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Insurance $14759
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3VECTOR PRODUCTION $72514
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4QUALITY CONTROL $35000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5CHIEF SCIENCE OFFICER $20000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6CLINIC RESEARCH COORDINATOR $13278
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt7director, business development $5000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt8PROCUREMENT ASSOCIATE $5000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt9RENT $4422
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt10LAB EQUIPMENT $3000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt11VECTOR TITER ASSAY $2610
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt12RESEARCH LAB SUPPLIES $2395
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt13RESEARCH EQUIPMENT RENT $1620
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt14LAB FEES $1325
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt15REFERENCE MATERIALS $1029
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt16administrative assistant $775
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Expenses.1001
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1002
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.1012
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Expenses.3
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6Other Expenses.4
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc7Other Expenses.5
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc8Other Expenses.6
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc9Other Expenses.7
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc10Other Expenses.8
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc11Other Expenses.9
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc12Other Expenses.10
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc13Other Expenses.12
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc14Other Expenses.13
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc15Other Expenses.14
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc16Other Expenses.15
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd0AAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/FederatedAssuranceLevelCd0FAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/IdentityAssuranceLevelCd0IAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd00
ReturnHeader/BuildTS02023-04-26 12:10:37Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0ERLINDA M GORDON
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02023-11-01
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0AVENI FOUNDATION
ReturnHeader/Filer/BusinessNameControlTxt0AVEN
ReturnHeader/Filer/EIN0830731767
ReturnHeader/Filer/PhoneNum08187263278
ReturnHeader/Filer/USAddress/AddressLine1Txt02700 NEILSON WAY 1227
ReturnHeader/Filer/USAddress/CityNm0SANTA MONICA
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CA
ReturnHeader/Filer/USAddress/ZIPCd090405
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0true
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0810908301
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0FIRST ADVISOR INC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0655 N CENTRAL AVE 17TH FLOOR
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0GLENDALE
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0CA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd091203
ReturnHeader/PreparerPersonGrp/PhoneNum08183307722
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0Lauren Lee
ReturnHeader/ReturnTs02023-11-01T22:12:08-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0ERLINDA M
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0GORDON
ReturnHeader/TaxPeriodBeginDt02022-01-01
ReturnHeader/TaxPeriodEndDt02022-12-31
ReturnHeader/TaxYr02022

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2022 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$144,595
Liabilities
-
Net assets
$144,595
Revenue
$90,641
Expenses
$195,739
Net income
-$105,098
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.84$0.01$0.83$1.15$0.70$0.45
2023Detailed filing. Detailed filing data is available for this year.$0.38$0.00$0.38$0.71$0.47$0.24
2022Detailed filing. Detailed filing data is available for this year.$0.14$0.14$0.09$0.20$0.11
2021Detailed filing. Detailed filing data is available for this year.$0.25$0.00$0.25$0.35$0.17$0.18
2020Detailed filing. Detailed filing data is available for this year.$0.06$0.00$0.06$0.15$0.35$0.20
2019Summary only. Only limited summary data is available for this year.$0.27$0.00$0.26$1.18$0.92$0.26
2018Detailed filing. Detailed filing data is available for this year.$0.01$0.01$0.01$0.00$0.01